1720 - 68Ga PSMA-11 PET/CT imaging for patients who are candidates for PSMA targeted therapy

Page last updated: 17 October 2023

Application Detail

Description of Medical Service

ILLUCCIX® is a kit for the preparation of 68Ga-PSMA-11 injection. The kit allows for non-invasive positron emission tomography/ computed tomography (PET/CT) for the imaging of prostate specific membrane antigen (PSMA)-expressing colon cancer. PSMA-11 is a synthetic urea-based peptide inhibitor of PSMA, it incorporates a chelate HBED-CC and binds to PSMA. Once PSMA-11 is radio labelled with the radioisotope gallium-68 (68Ga), it results in 68Ga-PSMA-11, made up to three individual patient doses, which can then be administered to patients intravenously as a PET-tracer to image PSMA-expressing prostate tumours, including metastatic diseases.

Description of Medical Condition

For Australian men, prostate cancer is the most commonly diagnosed cancer (>19000 cases pa) and the second most common cause of death via cancer (>3000 pa). More than 90,000 Australian men are estimated to be currently living with a diagnosis of prostate cancer, however, although breakthroughs in treatments mean that they are living longer (studies between 1986-1990 and 2011-2015 showed a survival rate increase from 59% to 95%) they are still afflicted with common side effects, such as; depression, anxiety, urinary incontinence, sexual impairments and bowel function impairments.

Overall quality of life for men diagnosed with prostate cancer declines over time, with 35-40% of men experiencing poorer physical and mental health 10 years after diagnosis, due to disease and treatments.

Reason for Application

New MBS item

Medical Service Type

Investigative technology

Previous Application Number/s

Not applicable

Associated Documentation

Application Form

Application Form (PDF 530 KB)
Application Form (Word 209 KB)

Consultation Survey

Consultation Survey (PDF 203 KB)
Consultation Survey (Word 28 KB)

PASC Consultation
Not applicable

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 16 February 2024 for it to be considered by MSAC at its April 2024 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation


Assessment Report


Public Summary Document


Meetings for this Application


Expedited - bypassed PASC


15-16 February 2024


4-5 April 2024